


Basal Cell Carcinoma, Diagnosis & Follow-Up









Introducing VivoAID™, bringing the power of AI to your clinic, making OCT skin imaging accessible to every dermatologist.

Major studies have shown that Optical Coherence Tomography (OCT) imaging enables superior diagnosis of early-stage BCC¹; together with superior detection of sub-clinical residual lesions on treatment follow-up² when compared with traditional clinical/dermatoscopic approaches. Its sensitivity and specificity in BCC diagnosis have been found to be non-inferior to traditional invasive biopsy³. Now, through the power of VivoAID, this rapid, non-invasive, cost-effective³ imaging becomes easier to learn, faster to use.

VivoAID is provided solely as an educational aid. OCT image analysis and interpretation remain the responsibility of the physician.



With VivoAID installed on your VivoSight Dx Pro system -

-  Full, non-invasive, HD scan acquired in just 15 seconds
-  Real-time placement of VivoAID image-markers during scan acquisition
-  Automated lesion penetration depth and volume calculation
-  Real-time 3-D volume rendering
-  Highly cost effective – reduces learning curve and examination times
-  Avoiding biopsy for many NMSC patients will simplify the patient journey and reduce your clinic's backlog

VivoSight Dx Pro with VivoAID makes OCT Skin Imaging accessible to every dermatologist.


Easier to learn, faster to use.

VivoAID – Reimagine BCC diagnosis & follow-up

Your route to faster, more sensitive BCC diagnosis

VivoAID has been designed to make OCT skin imaging easier to learn and even faster to use. New to OCT imaging? With VivoAID onboard, your learning curve to full clinic adoption will be swifter and easier. As an OCT-experienced user, the tools and major enhancements in VivoSight Dx Pro and VivoAID will aid and speed user-interpretation.


Only VivoSight Dx Pro skin imaging gives you The Whole Picture®




VivoSight AI >1mm penetration depth and 6mm x 6mm field of view in comparison with other OCT system's depth and FOV (0.4 x 1.5mm) shown by yellow box

The unrivalled 6x6mm field-of-view ensures that you can quickly and confidently see the entire lesion. Only VivoSight provides OCT skin imaging to a depth of >1mm, essential for BCC characterization.

Real-time 3D volume rendering enables rapid lesion visualization




3D volume rendering of OCT image data, vasculature (if D-OCT option activated) and VivoAID image markers is available in real-time as an aid to user-interpretation.



Provides context for clinical decision making

VivoSight Dx Pro provides simultaneous camera-view of the skin-lesion alongside 3D rendered OCT and skin surface imaging. This patient examination shows VivoAID image markers approaching a skin-lesion-margin drawn on the skin by the physician.



References:

- 1 Markowitz, O. et al. J Clin Aesthet Dermatol. 2015, 8(10): 14
- 2 Wolswijk T., et.al. JADV. (2023). 89:728

3 Adan, F. et.al. Lancet Oncology. 2022, 23(8) 1087

VivoSight Dx Pro is a Class 1 Laser Product



International

Michelson Diagnostics Ltd
Units 1&2 Maidstone Innovation Centre
Gidde Pond Way, Maidstone
Kent, ME14 5FY
United Kingdom
T: +44 (0)20 8308 1695
info@vivosight.com

United States

Michelson Diagnostics Inc.
Atascadero,
CA 93422
T: (408) 504-7391
info.us@vivosight.com

www.vivosight.com